NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
ID: 351647Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351647

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-101.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention, under a cooperative agreement mechanism (UG3/UH3). This funding opportunity aims to support multi-site exploratory and confirmatory clinical trials, as well as biomarker validation studies, focusing on innovative interventions for stroke prevention, treatment, and recovery. The initiative emphasizes collaboration within the NIH StrokeNet infrastructure, which includes coordinating and data management centers to facilitate recruitment and implementation of studies. Interested applicants must submit their proposals by November 19, 2026, and can find additional information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-101-Full-Announcement.html
    PAR-24-101.html
    The Department of Health and Human Services is issuing a Notice of Funding Opportunity (NOFO) inviting applications for NIH StrokeNet Clinical Trials aimed at stroke treatment, recovery, and prevention. Supported by the National Institutes of Health (NIH) and the National Institute of Neurological Disorders and Stroke (NINDS), this funding opportunity seeks multi-site exploratory and confirmatory clinical trials alongside biomarker validation studies. Successful applicants will work within the NIH StrokeNet infrastructure, which includes coordinating and data management centers, providing infrastructure for recruitment and implementation of studies. The NOFO utilizes a bi-phasic UG3/UH3 cooperative agreement mechanism, with an initial one-year planning phase followed by a potential six-year implementation phase based on milestone achievement. Applications must detail their project management and milestones, and eligibility includes various organizations and institutions, emphasizing diversity among applicants. Funds are contingent on appropriations, with budgets reflecting the actual needs of proposed projects. The call for proposals aims to advance research in stroke therapeutic innovations, emphasizing collaborative efforts among public and private entities within the NIH StrokeNet network.
    Similar Opportunities
    NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)." This initiative aims to support multi-site exploratory and confirmatory clinical trials that focus on innovative interventions, biomarker validation, and ancillary studies related to stroke prevention, treatment, and recovery. The program emphasizes collaboration within the NIH StrokeNet infrastructure to enhance patient recruitment and trial execution, addressing critical public health issues associated with stroke. Interested applicants must submit their proposals by November 19, 2026, and can find additional information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Stroke Preclinical Assessment Network (SPAN) to Support Translational Studies for Acute Cerebroprotection – Network Sites and Coordinating Center (U01- CT Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for the Stroke Preclinical Assessment Network (SPAN) to support translational studies focused on acute cerebroprotection in experimental models of acute ischemic stroke. This initiative aims to establish a collaborative network comprising a Coordinating Center and up to six peer-reviewed data collection sites, emphasizing rigorous methodologies and replication in preclinical testing of stroke treatments. The estimated total program funding is $500,000, with one award expected to be made, and interested applicants are encouraged to prepare their proposals ahead of the anticipated Notice of Funding Opportunity (NOFO) release, which is expected to be published by December 2025. For further inquiries, potential applicants can contact Francesca Bosetti at 301-496-1297 or via email at frances@mail.nih.gov.
    NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a forthcoming funding opportunity titled "NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required)" aimed at soliciting applications for research on exploratory and efficacy clinical trials that align with the mission of the National Institute of Neurological Disorders and Stroke (NINDS). This initiative will focus on evaluating various interventions, including drugs, biologics, devices, and therapies related to surgical, behavioral, and rehabilitation approaches. The opportunity is particularly significant for researchers with expertise in neurological disorders, as it encourages the development of meaningful collaborations and responsive projects in this critical health area. Interested applicants can reach out to Jeremy Brown, MD, via email at ExploratoryEfficacyTrials@ninds.nih.gov for further information, with the estimated synopsis posting date set for November 12, 2025, and applications expected to close by February 10, 2026.
    NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required), aimed at supporting multi-center clinical trials focused on neurological emergencies such as status epilepticus and traumatic brain injury. This initiative encourages collaboration with the NIH SIREN Clinical Coordinating Center to ensure efficient trial implementation, while applicants are expected to provide rigorous preclinical data and compelling rationales for their proposed interventions. The funding opportunity operates under a phased mechanism, with UG3 for planning and UH3 for execution, reflecting a commitment to enhance clinical research in emergency care. Interested applicants can find more information and application guidelines at the provided link, with a submission deadline of March 6, 2026, and no cost-sharing or matching requirements.
    NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the SIREN Neurologic Clinical Trials (UG3/UH3), aimed at developing multi-center clinical trials focused on neurological emergencies. This initiative encourages applications from a diverse range of entities, including universities, nonprofit organizations, and various community-serving institutions, to utilize the SIREN Network's infrastructure for efficient trial management, statistical support, and patient recruitment. The overarching goal is to enhance understanding and treatment of neurological emergencies through collaborative clinical research, ultimately improving patient outcomes and advancing healthcare practices. Interested applicants should note that the application deadline is March 6, 2026, and can find further details and guidelines at the provided NIH link or contact grantsinfo@nih.gov for inquiries.
    Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the clinical validation of candidate biomarkers for neurological and neuromuscular disorders through the U44 Cooperative Agreement mechanism. This initiative aims to rigorously validate biomarkers that have already been identified and for which detection methods have been developed, ensuring compliance with FDA guidelines to establish their clinical sensitivity and specificity. This program is crucial for advancing therapeutic development in the field of brain health, with funding potentially reaching $700,000 for Phase I and $1.5 million for Phase II projects. Interested applicants must adhere to specific submission guidelines and deadlines, with the application closing on June 22, 2026. For further information, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-096.html.
    Limited Competition: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a limited competition grant opportunity titled "Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States," aimed at advancing research on the relationship between stroke events and cognitive impairment in post-stroke populations. This initiative seeks to explore the clinical factors that may contribute to dementia outcomes in individuals who have experienced strokes, addressing a significant public health concern given that one in three people will have a stroke in their lifetime, with dementia affecting approximately 30% of post-stroke patients. The total estimated funding for this program is $10 million, with one award expected to be granted, and interested applicants who have previously received funding under RFA-NS-19-012 are encouraged to prepare their proposals ahead of the anticipated application period, which is expected to open on October 28, 2025, with a closing date of November 28, 2025. For further inquiries, potential applicants can contact Dr. Lina Garcia at lina.garcia@nih.gov or by phone at 301-496-9135.
    BRAIN Initiative: Clinical Studies to Advance Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for clinical studies aimed at advancing next-generation devices for recording and modulation in the human central nervous system, under the BRAIN Initiative. This initiative seeks to support small clinical trials that provide critical data necessary for the development of devices intended to treat central nervous system disorders, particularly those requiring an Investigational Device Exemption (IDE) from the FDA. The funding is crucial for enhancing neurotechnology and improving treatment outcomes, with NIH planning to allocate approximately $10 million annually for 5 to 7 awards, each with a maximum budget of $1.5 million per year for up to five years. Interested applicants can find more information and submit inquiries via grantsinfo@nih.gov, with applications due by September 28, 2026.
    Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)." This initiative aims to support the clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders, focusing on establishing their clinical sensitivity and specificity in accordance with FDA guidelines. The program is particularly significant as it seeks to enhance public health outcomes by facilitating the implementation of validated biomarkers in clinical settings, thereby addressing critical healthcare needs in these areas. Interested applicants should note that the application period opens on January 21, 2025, and closes on June 22, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-055.html.
    Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)" under Funding Opportunity Number PAR-24-097. This initiative aims to clinically validate candidate biomarkers for neurological diseases, focusing on establishing their clinical sensitivity and specificity, provided that preliminary conditions such as detection method development are met. The program emphasizes the importance of multidisciplinary collaborations and requires applicants to include a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in research teams. Interested applicants must submit their proposals by February 22, 2024, with project durations capped at five years. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-097.html.